BioSpace

Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal

Investors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral option to the Danish pharma’s early pipeline.

作者 BioSpace

1 分钟阅读
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察